John L. Villano, Md, Phd

This study tested whether a short course of radiation to one tumor site could help immunotherapy drugs work better in people with advanced lung or head/neck cancers. 76 participants received radiation within two weeks of starting their immunotherapy. The main goal was to see if t…

This phase 2 study tested a combination of two immunotherapy drugs, durvalumab and tremelimumab, in 14 adults with recurrent solid tumors that had a high number of genetic mutations. The goal was to see if the treatment could slow cancer growth compared to their prior therapy. Th…